HEALTHCARE UTILIZATION FOR CERVICAL CANCER IN BRAZIL: A NATIONAL ANALYSIS OF OUTPATIENT AND INPATIENT CARE
Author(s)
Paula Pungartnik, MD1, Zira M. Da Silva, Other1, Andre Della Santa, BSc1, Ana Luiza Bierrembach, PhD2, Rodrigo Gonçalves Queijo, BSc2, Cintia Parellada, PhD1.
1MSD Brazil, São Paulo, Brazil, 2Precision Data, São Paulo, Brazil.
1MSD Brazil, São Paulo, Brazil, 2Precision Data, São Paulo, Brazil.
OBJECTIVES: To describe outpatient and inpatient healthcare utilization for cervical cancer in Brazil in 2023.
METHODS: This retrospective observational study analyzed secondary data from the Brazilian public healthcare system. Outpatient visits (SIA) and hospitalizations (SIH) for cervical cancer were identified using ICD-10 codes and stratified by age group, with regional patterns described at the state level. Rates were calculated per 100,000 population, and age-standardized rates (ASRs) were estimated using the WHO World Standard Population.
RESULTS: In 2023, Brazil recorded 139,546 outpatient consultations (crude rate: 142.3/100,000; ASR: 111.4/100,000) and 27,888 hospitalizations (crude rate: 28.4/100,000; ASR: 22.6/100,000) related to cervical cancer. In both settings, utilization began to rise from ages 30-39 years (outpatient: 159.2; inpatient: 39.1/100,000), increased with age, and peaked among women aged 40-49 years (outpatient: 238.9; inpatient: 50.5/100,000) and 50-59 years (outpatient: 242.3; inpatient: 44.5/100,000), remaining high in those aged ≥60 years (outpatient: 214.0; inpatient: 35.5/100,000). Women aged <40 years accounted for 24.1% of outpatient visits and 29.0% of hospitalizations. Geographic variation was substantial. The highest outpatient ASRs were found in the North, particularly Amazonas (241.1) and Amapá (237.8), and in the Northeast, especially Sergipe (199.7) and Alagoas (187.8); Minas Gerais (188.4) also stood out in the Southeast. For inpatient care, the highest ASRs were observed in Rondônia (49.0), Espírito Santo (41.3), and Pernambuco (35.1), whereas the lowest were seen in Bahia (14.3) and Ceará (14.8).
CONCLUSIONS: Cervical cancer-related healthcare utilization in Brazil is substantial and varies markedly across regions, suggesting inequities in access and care. These differences highlight the need for equitable HPV vaccination strategies and access to screening and treatment to reduce future burden.
METHODS: This retrospective observational study analyzed secondary data from the Brazilian public healthcare system. Outpatient visits (SIA) and hospitalizations (SIH) for cervical cancer were identified using ICD-10 codes and stratified by age group, with regional patterns described at the state level. Rates were calculated per 100,000 population, and age-standardized rates (ASRs) were estimated using the WHO World Standard Population.
RESULTS: In 2023, Brazil recorded 139,546 outpatient consultations (crude rate: 142.3/100,000; ASR: 111.4/100,000) and 27,888 hospitalizations (crude rate: 28.4/100,000; ASR: 22.6/100,000) related to cervical cancer. In both settings, utilization began to rise from ages 30-39 years (outpatient: 159.2; inpatient: 39.1/100,000), increased with age, and peaked among women aged 40-49 years (outpatient: 238.9; inpatient: 50.5/100,000) and 50-59 years (outpatient: 242.3; inpatient: 44.5/100,000), remaining high in those aged ≥60 years (outpatient: 214.0; inpatient: 35.5/100,000). Women aged <40 years accounted for 24.1% of outpatient visits and 29.0% of hospitalizations. Geographic variation was substantial. The highest outpatient ASRs were found in the North, particularly Amazonas (241.1) and Amapá (237.8), and in the Northeast, especially Sergipe (199.7) and Alagoas (187.8); Minas Gerais (188.4) also stood out in the Southeast. For inpatient care, the highest ASRs were observed in Rondônia (49.0), Espírito Santo (41.3), and Pernambuco (35.1), whereas the lowest were seen in Bahia (14.3) and Ceará (14.8).
CONCLUSIONS: Cervical cancer-related healthcare utilization in Brazil is substantial and varies markedly across regions, suggesting inequities in access and care. These differences highlight the need for equitable HPV vaccination strategies and access to screening and treatment to reduce future burden.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH245
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Reproductive & Sexual Health